Authors : Dr. M. Naga Pradeep; Dr. S. Dimple; Dr. A. Nanda Gopal Reddy

Volume/Issue : Volume 10 - 2025, Issue 1 - January

---

Google Scholar : https://tinyurl.com/43zv7par

Scribd : https://tinyurl.com/2nfv3ckn

DOI : https://doi.org/10.5281/zenodo.14769374

---

Abstract : This research focuses on HDL cholesterol levels in ischemic and hemorrhagic strokes and their impacts,This study included 100 participants with ischemic and hemorrhagic strokes for comparative analysis,The results indicated distinct differences in HDL levels between the two types of strokes,Elevated HDL levels may correlate with reduced stroke risk, suggesting a protective role.

References :

1. WHO MONICA Project Investigators. World Health Organisation MONICA Project. (monitoring trends and determinants in Cardiovascular Disease) J ClinEpidemeol 41,105-114 ,1988
2. Ezzati M, Lopez A, Rodgers A et al. Comparative quantification of health risks. Global and regional burden of disease attributable to major risk factors. Geneva: WHO 2004
3. Gupta R, Joshi P, Mohan V, Reddy S, Yusuf S. Epidemiology and causation of coronary heart disease and stroke in India. Heart 2008; 94: 16- 26
4. Dalal P et al. Population-bases stroke survey in Mumbai, India: Incidence and 28-day case fatality.Neuroepidemiology 2008; 31: 254-61
5. Banerjee T, Das S. Epidemiology of stroke in India. Neurology Asia 2006; 11: 1-4
6. Bharucha N, Kuruvilla T. Epidemiology of stroke in India. Neurol J Southeast Asia 1998;3: 5-8
7. V. L. Feigin, “Stroke in developing countries: can the epidemic be stopped and outcomes improved?” Lancet Neurology, vol. 6, no. 2, pp. 94–97, 2007
8. Bath P, Lees K. ABC of arterial and venous disease. Acute stroke BMJ 2000; 320:920- 9239. Indian Council for Medical Research.
9. Stroke. in: Assessment of the burden of non communicable diseases: Final project report. New Delhi: Indian Council of Medical Research; 2004. p. 18-22.
10. Donnan GA, Fisher M, Macleod M, Davis SM. "Stroke". Lancet 2008; 371 (9624): 1612–23.
11. Shuaib A, Hachinski V. Mechanisms and management of stroke in the elderly. CMAJ 1991; 145(5): 433–43.
12. Stam J. Thrombosis of the cerebral veins and sinuses. The New England Journal Of Medicine 2005; 352 (17): 1791–8.
13. Guercini F, Acciarresi M, Agnelli G, Paciaroni M. Cryptogenic stroke timeto determine aetiology. Journal of Thrombosis and Haemostasis 2008; 6 (4): 549–54.
14. Sacco RL, Ellenberg JH, Mohr JP, Tatemichi TK, Hier DB, Price TR, Wolf PA: Infarcts of undetermined cause: the NINCDS Stroke Data Bank. Ann Neurol 1989;25:382–390.
15. Bamford J, Sandercock PA, Dennis MS, Burn J, Warlow CP: Classification and natural history of clinically identifiable subtypes of brain infarction. Lancet 1991;337:1521–1526.
16. Adams HP, Bendixen BH, Kappelle LJ, Biller J,Love BB, Gordon DL, Marsh EE: Classification of subtype of acuteischemic stroke:definitions for use in a multicenter clinical trial.Stroke 1993;24:35-41
17. Rosamond W, Flegal K, Furie K et al. Heart disease and stroke statistics 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008; 117(4):e25–146.
18. Kiely DK, Wolf PA, Cupples LA, Beiser AS, Myers RH. Familial aggregation of stroke. The Framingham Study. Stroke 1993;24:1366-1371.
19. Kalimo H, Viitanen M, Amberla K et al. CADASIL: hereditary disease of arteries causing brain infarcts and dementia. NeuropatholApplNeurobiol 1999;25(4):257–65.
20. Burchfiel CM, Curb JD, Rodriguez BL et al. Glucose intolerance and 22- year stroke incidence. The Honolulu heart program. Stroke1994;25(5):951– 7.
21. Kissela BM, Khoury J, Kleindorfer D et al. Epidemiology of ischemic stroke in patients with diabetes: the greater Cincinnati/Northern Kentucky stroke study. Diabetes Care2005; 28(2):355–9.
22. Chobanian AV, Bakris GL, Black HR et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure the JNC 7 report. JAMA 2003;289(19):2560–72.
23. Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Bibliography
24. Vasan RS, LarsonMG, Leip EP et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med2001;345(18):1291–7.25.Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA.
25. Independent risk factors for atrial fibrillation in a population based cohort. The Framingham Heart Study. JAMA 1994;271:840-844.
26. Lin HJ, Wolf PA, Kelly-Hayes M et al. Stroke severity in atrial fibrillation. The Framingham study. Stroke 1996;27(10):1760–4.
27. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. ArchIntern Med 1987; 147 (9): 1561–4.
28. Loh E, Sutton MSJ, Wunncc et al. Ventricular dysfunction and the risk of stroke after MI. N EngL I Med 1997;336(4):256-7.
29. Hillbom M, Numminen H, Juvela S. Recent heavy drinking of alcohol and embolic stroke.Stroke 1999;30(11):2307–12.
30. Shinton R, Beevers G. Meta-analysis of relation between cigarette smoking and stroke. BMJ 1989;298:789-794.
31. Choi DW, Rothman SM.AnnRev.The role of glutamate neurotoxicity in hypoxic ischemic neuronal death. Neurosci. 1990;13:171–182.
32. Bots ML, Elwood PC, Nikitin Y et al. Total and HDL cholesterol and risk of stroke. EUROSTROKE: a collaborative study among research centres in Europe. J Epidemiol Community Health 2002;56(Suppl 1):i19–24.
33. Shahar E, Chambless LE, Rosamond W et al. Plasma lipid profile and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Stroke 2003;34(3):623–31.
34. Kurth T, Gaziano JM, Berger K et al. Body mass index and the risk of stroke in men. ArchIntern Med 2002; 162(22):2557–62.
35. Abbott RD, Rodriguez BL, Burchfiel C et al. Physical activity in older middle-aged men and reduced risk of stroke. The Honolulu Heart Program.Am J Epidemiol 1994
36. Grau AJ, Buggle F, Ziegler C et al. Association between acute cerebrovascular ischemia and chronic and recurrent infection. Stroke 1997;28(9):1724–9.
37. Lindsberg PJ, Grau AJ. Inflammation and infections as risk factors for ischemic stroke. Stroke 2003;34(10):2518–32.
38. Weber M, Hayem G, DeBandt M et al. The family history of patients with primary or secondary antiphospholipid syndrome (APS). Lupus 2000; 9(4): 258–63.
39. GilesWH, Croft JB, GreenlundKJ, et al. Total homocysteine concentration and the likelihood of nonfatal stroke: results from the Third National Health and Nutrition examination survey, 1988–1994. Stroke 1998;29(12):2473–7.
40. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002;288(16):2015–22.
41. Selhub J, Jacques PF,Wilson PW, et al. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993;270(22):2693–8.
42. Jacques PF, Rosenberg IH, Rogers G, et al. Serum total homocysteine concentrations in adolescent and adult Americans: results from the third National Health and Nutrition examination survey. Am J Clin Nutr 1999;69(3):482–9.
43. Seeger MD, Barratt BS, Lawson GA, Klingman N. The relationship between carotid plaque composition, morphology and neurological symptoms. JSurg Res1995;58:330 - 336
44. Gideon R Hajer, Yolanda van der Graaf, Jobien K Olijhoek, Marianne C Verhaar, Frank L J Visseren. The SMART Study Group:Heart 2007;93:216-220.
45. Joseph L, Daniel stainberg. Role of oxidized low-density lipoproteins in atherogenisis, J. Clin Invest 88; 1991; 1785-1792.
46. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 1999;22:391–7.
47. Lipton P.Ischemic cell death in brain neurons. Physiol Rev. 1999;79:1431– 568.
48. 10. Bruno V, Battaglia G, Copani A, et al. Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs. J Cereb Blood Flow Metab. 2001;21:1013–33.
49. Brott T, Broderick J, Kothari R, et al. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke. 1997;28:1-5. 50. Kazui S, Naritomi H, Yamamoto H, et al.
50. Enlargement of spontaneous intracerebral hemorrhage: incidence and time course. Stroke. 1996;27:1783- 7.
51. Kazui S, Minematsu K, Yamamoto H, et al. Predisposing factors to enlargement of spontaneous intracerebral hematoma. Stroke. 1997;28:2370- 5.
52. Becker KJ, Baxter AB, Bybee HM, et al. Extravasation of radiographic contrast is an independent predictor of death in primary intracerebral hemorrhage. Stroke. 1999;30:2025-32.
53. Ohwaki K, Yano E, Nagashima H, et al. Blood pressure management in acute intracerebral hemorrhage: relationship between elevated blood pressure and hematoma enlargement. Stroke. 2004; 35:1364-7.
54. Toyoda K, Okada Y, Minematsu K, et al. Antiplatelet therapy contributes to acute deterioration of intracerebral hemorrhage. Neurology. 2005; 65: 1000- 04.
55. Yasaka M, Minematsu K, Naritomi H, et al. Predisposing factors for enlargement of intracerebral hemorrhage in patients treated with warfarin. Thromb Haemost. 2003; 89: 278-83.
56. Flibotte JJ, Hagan N, O’Donnell J, et al. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology. 2004; 63: 1059-64.
57. Elliott J, Smith M. The acute management of intracerebral hemorrhage: a clinical review. Anesth Analg. 2010; 110(5): 1419-27. 58. Qureshi AI, Ali Z, Suri MF, Shuaib A, Baker G, Todd K, et al.
58. Extracellular glutamate and other amino acids in experimental intracerebral hemorrhage: an in vivo microdialysis study. Crit Care Med. 2003;31:1482– 1489.
59. Aronowski J, Hall CE. New horizons for primary intracerebral hemorrhage treatment: experience from preclinical studies. Neurol Res. 2005; 27:268 – 279.
60. Felberg RA, Grotta JC, Shirzadi AL, Strong R, Narayana P, Hill-Felberg SJ, et al. Cell death in experimental intracerebral hemorrhage: the “black hole” Model of hemorrhagic damage. Ann Neurol. 2002;51:517–524.
61. Huang FP, Xi G, Keep RF, Hua Y, Nemoianu A, Hoff JT. Brain edema after experimental intracerebral hemorrhage: role of hemoglobin degradation products. J Neurosurg. 2002;96:287–293.
62. Longo, Fauci ,Kasper,Hauser,Loscalzo.cerebrovascular diseases. Harrisons principle of internal medicine 17;2:2513
63. Adams H, Davis P, Hansen M, et al. (1999). "Baseline NIH Stroke Scale score strongly predicts outcome after stroke - A report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST)". Neurology. 53 (1): 126–131
64. Glymour M, Berkman L, Ertel K, Fay M, Glass T, Furie K (2007). "Lesion characteristics, NIH Stroke Scale, and functional recovery after stroke". American Journal of Physical Medicine & Rehabilitation. 86 (9): 725–733.
65. Martin-Schild S, Albright KC, Tanksley J, Pandav V, Jones EB, Grotta JC, Savitz SI (2011). "Zero on the NIHSS does not equal the absence of stroke". Ann Emerg Med. 57 (1): 42–5.
66. Yun Shen,Lizheng shi,Elizabeth Nauman. Inverse Association Between HDL (High-Density Lipoprotein) Cholesterol and Stroke Risk Among Patients With Type 2 Diabetes Mellitus, 2019;50:291–297
67. Kathleen M.Botham; Lipid transport and storage ; Harper’s illustrated biochemistry; Robert K.Murray, David A Bende et al; 28th edition , Mc Graw Hill Medical pub, pge 216-217.
68. Natalia Ferner, Jordia Canyrs, et al; Serum PON activity, A new additional test for the improved evaluation of chronic liver damage; Clinical chemistry, 48;2;261-263 (2002)
69. Primo-Parmo, S.L; R.C.Sorenson et al ; The human serum PON/arylesterase gene (PON-1) in the member of a multi gene family, Genomics, 33; 498-507 (1996)
70. Marija Grdic Rajkovic, LadaRumora et al; The paraoxonase 1,2,3 in human; Biochemia medica (2): 122-30; march 14, 2011.
71. Andrew D.Watson, Judith A.Berliner et al; Protective effect of High Density Lipoprotein Associated Paraoxonase; J. Clin. Invest. Vol 96, Dec 1995, 2882-2891.72. Edward A. Fisher , Jonathan; E. Feig
72. HDL Function, Dysfunction, and Reverse Cholesterol Transport Arterioscler Thromb Vasc Biol. 2012 December ; 32(12): 2813–2820.
73. Chieko Mineo, Hiroshi Deguchi ;Endothelial and Antithrombotic Actions of HDL, Circ Res. 2006;98:1352-1364.
74. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977;62:707– 714.
75. Goya Wannamethee ;A. Gerald Shaper,HDL-Cholesterol, Total Cholesterol, and the Risk of Stroke in Middle-Aged British Men Stroke; 2000;31:1882–1888
76. David Curb1 Robert D. Abbott ;High Density Lipoprotein Cholesterol and the Risk of Stroke in Elderly Men The Honolulu Heart Program; publication American Journal of Epidemiology ;2004 Vol. 160, No. 2
77. Shadi Yaghi, and Mitchell S.V. Elkind Lipids and Cerebrovascular Disease: Research and Practice ;Stroke. 2015 November; 46(11): 3322– 3328.
78. Xiang Wang;Yan Dong;Cholesterol Levels and Risk of Hemorrhagic Stroke A Systematic Review and Meta-Analysis Stroke. 2013;44:1833–1839
79. Sprecher DL. Raising high density lipoprotein cholesterol with niacin and fibrates: a comparative review. Am J Cardiol 2000; 86:46L–50L.